Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy

A Guzman-Aranguez, P Loma and J Pintor

Department of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain

RNA interference (RNAi) can be used to inhibit the expression of specific genes in vitro and in vivo, thereby providing an extremely useful tool for investigating gene function. Progress in the understanding of RNAi-based mechanisms has opened up new perspectives in therapeutics for the treatment of several diseases including ocular disorders. The eye is currently considered a good target for RNAi therapy mainly because it is a confined compartment and, therefore, enables local delivery of small-interfering RNAs (siRNAs) by topical instillation or direct injection. However, delivery strategies that protect the siRNAs from degradation and are suitable for long-term treatment would be helpful to improve the efficacy of RNAi-based therapies for ocular pathologies. siRNAs targeting critical molecules involved in the pathogenesis of glaucoma, retinitis pigmentosa and neovascular eye diseases (age-related macular degeneration, diabetic retinopathy and corneal neovascularization) have been tested in experimental animal models, and clinical trials have been conducted with some of them. This review provides an update on the progress of RNAi in ocular therapeutics, discussing the advantages and drawbacks of RNAi-based therapeutics compared to previous treatments.

Abbreviations

AMD, age-related macular degeneration; Apaf-1, apoptotic protease-activating factor-1; CNV, choroidal neovascularization; CTGF, connective tissue growth factor; DR, diabetic retinopathy; dsRNA, double-stranded RNA; ECM, extracellular matrix; HIF-1α, hypoxia-inducible factor-1α; IOP, intraocular pressure; ONC, optic nerve crush; POAG, open-angle glaucoma; RGC, retinal ganglion cell; RISC, RNA-induced silencing complex; RNAi, RNA interference; RP, retinitis pigmentosa; Smad, signalling matthers against decapentaplegic; SPARC, secreted protein acidic and rich in cysteine; TLR3, toll-like receptor 3; TM, trabecular meshwork; TXNIP, thioredoxin interacting protein

Introduction

RNA interference (RNAi) technology has been used to elucidate gene function, to generate model systems and to identify new molecular targets. In addition, RNAi is currently progressing from basic research to potential therapeutic applications. Because any gene that causes or contributes to a disease is susceptible to suppression by RNAi, RNAi therapy represents a promising biomedical strategy for treating a diverse range of diseases including cancer, cardiovascular diseases, neurodegenerative diseases, inflammatory conditions, viral infections and ocular diseases (Guo et al., 2010). In particular, the accessibility of the eye facilitates small-interfering RNA (siRNA) delivery, and naked siRNA has been efficiently applied by topical administration to the anterior segment or by intravitreal injection to the posterior segment (de Fougerolles, 2008). As the localized delivery of siRNA to the eye is less challenging than for other tissues, there has been significant progress made towards its use as a therapeutic procedure for eye diseases. In fact, several siRNA-based therapeutic agents for ocular disorders have already reached clinical trials (http://www.allergan.com, http://www.opko.com, http://www.quarkpham.com; Table 1).
Molecular mechanism of RNAi

RNAi is an evolutionary conserved post-transcriptional gene-silencing pathway that was first demonstrated in the nematode worm Caenorhabditis elegans in 1998 (Fire et al., 1998). Soon after, RNAi was also shown to occur in mammalian cells (Elbashir et al., 2001a).

RNAi is a fundamental pathway by which sequence-specific siRNA is able to target and cleave complementary mRNA (Figure 1). RNAi is triggered by the presence of long pieces of double-stranded RNA (dsRNA), which are cleaved into the fragments known as siRNA [21–23 nucleotides (nt) long] by an RNase III enzyme called Dicer (Ketting et al., 2005), generating the single-stranded antisense strand. This guide strand is bound within the catalytic RIC complex in which it forms a complex with an endonuclease Argonaute 2, which hydrolyses the target mRNA. RISC activation is initiated by (i) a protein, thus propagating gene silencing and making this a very potent process.

Despite the exceptional utility that RNAi technology appears to offer for the treatment of ocular pathologies, there are a number of critical issues that must be taken into account before siRNAs can be used clinically. These include minimizing off-target effects, increasing the stability of synthetic siRNA and optimizing siRNA delivery.

Off-target effects

Although specificity should be one of the main characteristics of RNAi, non-specific silencing resulting from binding of siRNA to sequences other than the specific target sequence can occur. Off-target effects have mostly been shown to be due to 3′-untranslated region (UTR) seed matches, but not to the overall homology between siRNA and its target (Birmingham et al., 2006). Avoiding siRNA seed matches with mRNA 3′-UTRs by using online 3′-UTRs search algorithms would, potentially, reduce these detrimental off-target effects. Moreover, it has been reported that a predominance of specific motifs such as -UGGC- and other -AU-rich pentamers, including -AUUUG, GUUUU, AUUUU, UUUUU, GUUUG-, can induce a toxic phenotype in cells (Fedorov et al., 2006); thus the use of such motifs should, if possible, be minimized.

Other non-specific effects

Exposure to long dsRNA (>30 nt) can trigger an innate immune response via activation of toll-like receptors (TLR; Alexander et al., 2011) (Alexopoulou et al., 2001). The 21 nt siRNAs can activate TLR3 (Kleinman et al., 2008; Cho et al., 2001b), leading to subsequent degradation of the cleaved mRNA transcript by cellular exonucleases (Orban and Izaurralde, 2005). The activated RISC complex is capable of binding and destroying hundreds of complementary mRNA, which, in turn, abolishes the expression of the encoded protein, thus propagating gene silencing and making this a very potent process.

Clinical trials performed with siRNAs for ocular disease treatment

Table 1

<table>
<thead>
<tr>
<th>Ocular diseases</th>
<th>siRNA Target</th>
<th>Company</th>
<th>Status</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td>SYL040012 β2-Adrenoceptor</td>
<td>Sylentis</td>
<td>Phase II (ongoing)</td>
<td>Pañeda et al., 2013</td>
</tr>
<tr>
<td>AMD</td>
<td>Bevasiranib VEGF</td>
<td>Opko Health, Inc.</td>
<td>Phase III (halted)</td>
<td>Brucker, 2006; ClinicalTrials, 2008</td>
</tr>
<tr>
<td>AMD</td>
<td>siRNA-027 VEGF receptor</td>
<td>Allergan</td>
<td>Phase II (halted)</td>
<td>Kaiser et al., 2010</td>
</tr>
<tr>
<td>AMD</td>
<td>PF-655 RTP801</td>
<td>Quark Pharmaceuticals</td>
<td>Phase II (completed)</td>
<td>Nguyen et al., 2012b; 2012c</td>
</tr>
<tr>
<td>DR</td>
<td>PF-655 RTP801</td>
<td>Quark Pharmaceuticals</td>
<td>Phase II (completed)</td>
<td>Nguyen et al., 2012a</td>
</tr>
</tbody>
</table>

All siRNAs for AMD and DR treatment were administered by intravitreal injection. siRNA-027, also known as AGN211745; PF-655.
2009) and TLR7/8 (Hornung et al., 2005; Sioud, 2005), which produce cytokines upon stimulation. The presence of certain sequence motifs in the siRNAs might predispose them to initiate innate immune response. For example, siRNA sequence motifs such as 5′-GUCCUUCAA-3′ and 5′-UGUGU-3′ have been identified as having immunostimulating properties (Hornung et al., 2005; Judge et al., 2005). To prevent the activation of innate cellular immunity, these sequences should be avoided in siRNA design. Likewise, it has been shown that the introduction of some chemical modifications (2′-O-methyl, 2′-deoxy, etc.; Judge et al., 2006) or ensuring that siRNAs have a 2 nt 3′ overhang (Marques et al., 2006) can avert immune responses. Additionally, immune system recognition can be avoided by the use of siRNA duplexes shorter than 21 nt (Kleinman et al., 2012).

**Stability**

The gene-silencing effect of siRNA is transient with transfected siRNAs typically effective for about 3–7 days before they are naturally degraded. Therefore, there have been attempts to prolong the gene-silencing activity of siRNAs by the incorporation of chemical modifications to increase the stability of the siRNA molecules without compromising their gene-silencing potency. These modifications include the introduction of phosphorothioate backbone linkages at the 3′-end of the RNA strands (Gaglione and Messere, 2010), boranophosphate backbone modifications (Hall et al., 2004) or the incorporation of chemical modifications at the 2′ position of the ribose such as 2′-O-methyl or 2′-fluoro (Chiu and Rana, 2003). However, even chemically modified siRNAs can be susceptible to degradation as some endonucleases present in the extracellular environment, such as the vitreous humour, are able to avoid the terminal protection by bypassing them (Beverly et al., 2006).

**Delivery**

In the case of the eye, because of its accessibility, siRNA administration and delivery is clearly easier than in other organ/tissue targets. Important benefits of localized application of siRNAs include the potential for both higher bioavailability given the proximity to the target tissue and reduced adverse effects, which are typically associated with systemic administration.

Direct instillation of siRNA into the ocular surface has been used for the treatment of ocular surface and anterior segment disorders in vivo (Crooke et al., 2009; Martin-Gil et al., 2012). However, topical ocular administration of any compound, siRNAs included, is limited by ocular anatomic constraints and physiological protective mechanisms (Guzman-Aranguez et al., 2013). For this reason, new strategies such as iontophoresis (Myles et al., 2005) or the use of cell-penetrating peptides (Johnson et al., 2008) are being sought to improve the ocular delivery of siRNA.
Delivery of siRNAs by topical instillation to the posterior segment is truly challenging, because of the relatively large distance that the siRNAs have to go through the vitreous body before they reach the retina. The most common strategy used is direct intravitreal injection of siRNAs, which is less invasive than subretinal injection and bypasses the corneoscleral barriers (Tolentino et al., 2004). Successful knock-down of VEGF receptor-1 (VEGFR1) after injection of naked stability-modified VEGFR1 siRNA has been demonstrated in mouse models (Shen et al., 2006). This route of administration is also currently being used in clinical trials with siRNAs targeting VEGF (Brucker, 2006), VEGFR1 (Kaiser et al., 2010) and hypoxia-inducible RBP801 genes (Nguyen et al., 2012b). As chemically modified siRNAs can also be degraded by vitreous endonucleases (Beverly et al., 2006), siRNA-based treatments of posterior segment diseases could require multiple intravitreal injections, similar to conventional treatments. This need for multiple injections increases the potential for cataract, retinal detachment, vitreous haemorrhage and endophthalmitis (Kurz and Ciulla, 2002). Consequently, a sustained release of siRNAs for extended periods of time could be very helpful. To achieve this, encapsulation of siRNAs into non-viral nanocarriers might be a valuable option for intravitreal delivery. However, negatively charged glycosaminoglycans of the vitreous can interact with cationic carriers, thus limiting their diffusion and promoting their aggregation (Pitkanen et al., 2003; Peeters et al., 2005; 2007). The shielding of these polystyrene nanospheres and lipoplexes with polyethylene glycol (PEG) can prevent their aggregation (Peeters et al., 2005), but, unfortunately, peylation can also prevent the cellular uptake of the complexes (Deshpande et al., 2004) as well as their endosomal transport and release (Shi et al., 2002; Song et al., 2002). This limitation can be overcome by using exchangeable PEG lipids or by coupling the PEG to carriers via a pH-sensitive linker (Peeters et al., 2007).

However, more recently promising results have been reported using TransIT-TKO transfection reagent as a carrier for intravitreal siRNA delivery into the mouse retina after intravitreal injection (Turchinovich et al., 2010).

Therapeutic applications of RNAi in ocular disorders

Recent findings have highlighted the effectiveness of RNAi in therapeutically appropriate conditions, such as the treatment of eye diseases. Indeed, the first clinical application of RNAi was directed at the treatment of the wet age-related macular degeneration (AMD). Since then, therapies based on RNAi are also being developed for other ocular diseases such as diabetic retinopathy (DR), retinitis pigmentosa (RP), corneal neovascularization, fibrotic eye diseases or glaucoma (Table 2).

In this section, we review the main progress in RNAi-based therapies for ocular disorders and discuss the advances as well as the challenges in this field.

Glaucoma

Glaucoma consists of a group of progressive optic neuropathies that are characterized by progressive and permanent blindness resulting from the slow death of retinal ganglion cells (RGCs) and their axons, which form the optic nerve (Quigley, 2011).

The pathophysiology of glaucomatous neurodegeneration is not fully understood, and the factors contributing to its progression are not yet well characterized. The level of intraocular pressure (IOP) is related to the death of RGCs and optic nerve fibres; high IOP can cause blockade at the lamina cribrosa of axonal protein transport, causing neuronal RGC death by trophic insufficiency (Johnson et al., 2009). Independently or in addition to IOP, other factors contributing to neurodegeneration include local ischaemia-hypoxia, excessive stimulation of the glutamatergic system, alterations in glial cells and aberrant immunity (Weinreb and Khaw, 2004).

IOP is the only proven treatable risk factor (The AGIS Investigators, 2000; Heijl et al., 2002; Kass et al., 2002), and lowering IOP is the main approach for reducing disease progression. IOP is determined by the balance between the aqueous humour secreted into the eye by the ciliary body (Macknight et al., 2000) and the amount that is drained from the eye via the two major outflow pathways: the trabecular meshwork (TM; Tamm, 2009) and the uveoscleral pathway (consisting of the iris root, longitudinal ciliary muscle, anterior choroid and sclera; Alin and Nilsson, 2009). IOP is in a steady state when the rate of aqueous inflow is the same as the rate of aqueous outflow (Moses, 1981; Kiel et al., 2011). IOP reduction therapy is achieved through pharmacological treatment, laser therapy or surgical operation ( trabeculectomy; Quigley, 2011).

Pharmacological treatment of glaucoma lowers IOP by decreasing the rate of aqueous inflow and/or increasing the rate of aqueous outflow (Figure 2). Drugs reducing the production of the aqueous humour include β-adrenoceptor blockers (timolol), carbonic anhydrase inhibitors (dorzolamide, brinzolamide) and α-adrenoceptor agonists (brimonidine, apraclonidine). β-Adrenoceptor blockers reduce aqueous humour secretion by inhibiting the activity of the predominant β-adrenoceptor in the ciliary epithelium (Nathanson, 1981). IOP has been noted to follow a 24 h rhythm with a nocturnal increase, at least in part, due to the supine position effected while sleeping (Liu et al., 1998; 1999; Fan et al., 2011). Unfortunately, β-adrenoceptor blockers are only effective during the day and not during the night. In addition, although they can reduce ocular perfusion pressure (Liu et al., 2004), they can also have substantial cardiovascular and respiratory side effects, especially in the elderly (Weinreb and Khaw, 2004).

Carbonic anhydrase inhibitors inhibit the activity of carbonic anhydrase 2 in the non-pigmented ciliary epithelium, slowing local bicarbonate production and so decreasing sodium and fluid transport, thus reducing aqueous humour secretion (Silver, 1998). Carbonic anhydrase inhibitors are sulphonamide-based drugs; therefore, they should not be used in individuals allergic to sulphonamides. Likewise, their use should be restricted in subjects with severe renal disease and patients with compromised endothelium (Mincione et al., 2008). Another approach to reduce aqueous humour formation is the use of α2-adrenoceptor antagonists. These decrease aqueous humour inflow and also appear to increase uveoscleral outflow (Toris et al., 1999). Topical α2-adrenoceptor agonists are associated with allergic conjunc-
Pharmacological agents that improve aqueous humour outflow include cholinoceptor agonists and PGs (Weinreb and Khaw, 2004). Cholinoceptor agonists act on muscarinic receptors on the ciliary muscle to increase outflow through the TM, but they have substantial ocular side effects such as miosis, myopia, brow ache and dimming of vision (Zhang et al., 2012). PGF₂α analogues are the most effective outflow drugs and have been approved for clinical use. These drugs reduce IOP by stimulation of aqueous humour drainage, primarily through the uveoscleral outflow. These PG analogues activate matrix metalloproteinases, which then remodel the extracellular matrix (ECM) and reduce outflow resistance, allowing the aqueous humour to flow out via this route (Weinreb et al., 2002). The most common adverse reactions are conjunctival hyperaemia, lengthening and thickening of eyelashes, and changes in eye colour (Wistrand et al., 1997).

Therefore, all the drugs indicated can have various undesirable effects and their efficacy is also likely to be reduced after prolonged use (Quigley, 2011). Thus, there is the need to discover novel agents from the presently available pharmaceutical classes as well as potential new targets that should be validated and, subsequently, lead to new therapeutic alternatives. In this context, siRNA-based therapy for glaucoma is being explored. Initially, the main focus was to use it to lower IOP either by decreasing the production of aqueous humour or by improving its outflow. Hence, the effects of SYL040012 siRNA, which targets β₂-adrenoceptors in the ciliary epithelium, on aqueous humour production were investigated. Topical instillation of the SYL040012 siRNA was found to decrease IOP in rabbits by around 30% as compared with the control (Mediero et al., 2009; Pintor, 2011).

<table>
<thead>
<tr>
<th>Ocular diseases</th>
<th>Target</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td>RhoA</td>
<td>Liu et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Cochlin</td>
<td>Goel et al., 2012</td>
</tr>
<tr>
<td></td>
<td>β₂-Adrenoceptor</td>
<td>Mediero et al., 2009; Pintor, 2011</td>
</tr>
<tr>
<td></td>
<td>Na-K-ATPase</td>
<td>Mediero et al., 2009</td>
</tr>
<tr>
<td></td>
<td>Purine receptor P₂Y₂</td>
<td>Martin-Gil et al., 2012</td>
</tr>
<tr>
<td></td>
<td>c-Jun</td>
<td>Lingor et al., 2005</td>
</tr>
<tr>
<td></td>
<td>Apoptosis regulator Bax</td>
<td>Lingor et al., 2005</td>
</tr>
<tr>
<td></td>
<td>Apaf-1</td>
<td>Lingor et al., 2005</td>
</tr>
<tr>
<td></td>
<td>Caspase-2</td>
<td>Ahmed et al., 2011</td>
</tr>
<tr>
<td></td>
<td>TGF-β2</td>
<td>Nakamura et al., 2004</td>
</tr>
<tr>
<td></td>
<td>IxKβ kinase β</td>
<td>Ye et al., 2010</td>
</tr>
<tr>
<td>Fibrotic eye by glaucoma filtration surgery</td>
<td>Rhodopsin</td>
<td>Tessitore et al., 2006; O’Reilly et al., 2007; Mao et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Retinal degeneration slow-peripherin</td>
<td>Petrs-Silva et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Guanylate cyclase 2</td>
<td>Tosi et al., 2011</td>
</tr>
<tr>
<td></td>
<td>Cyclic nucleotide-gated ion channels</td>
<td>Tosi et al., 2011</td>
</tr>
<tr>
<td>Retinal degeneration slow-peripherin</td>
<td>VEGF</td>
<td>Reich et al., 2003</td>
</tr>
<tr>
<td></td>
<td>VEGFR1</td>
<td>Shen et al., 2006</td>
</tr>
<tr>
<td></td>
<td>RTP801</td>
<td>Nozaki et al., 2006</td>
</tr>
<tr>
<td>Retinal degeneration slow-peripherin</td>
<td>VEGF</td>
<td>Reich et al., 2003; Nozaki et al., 2006</td>
</tr>
<tr>
<td></td>
<td>VEGFR1</td>
<td>Shen et al., 2006</td>
</tr>
<tr>
<td></td>
<td>RTP801</td>
<td>Braffman et al., 2004</td>
</tr>
<tr>
<td>Retinal degeneration slow-peripherin</td>
<td>HIF-1α</td>
<td>Jiang et al., 2009</td>
</tr>
<tr>
<td></td>
<td>Fibronectin</td>
<td>Roy et al., 2003</td>
</tr>
<tr>
<td>Retinal degeneration slow-peripherin</td>
<td>Connective tissue growth factor</td>
<td>Yang et al., 2010a; 2010b; Winkler et al., 2012</td>
</tr>
<tr>
<td></td>
<td>TXNIP</td>
<td>Perrone et al., 2010; Sbai et al., 2010; Devi et al., 2012</td>
</tr>
<tr>
<td>Corneal neovascularization</td>
<td>VEGF</td>
<td>Kim et al., 2004; Singh et al., 2007; Zuo et al., 2010; Qazi et al., 2012</td>
</tr>
<tr>
<td></td>
<td>VEGFR1</td>
<td>Kim et al., 2004</td>
</tr>
<tr>
<td></td>
<td>HIF-1α</td>
<td>Chen et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Cytochrome P450 enzyme CYP4B1</td>
<td>Seta et al., 2007</td>
</tr>
<tr>
<td></td>
<td>Cannabinoid CB₁ receptor</td>
<td>Pisanti et al., 2011</td>
</tr>
</tbody>
</table>

Table 2
Summary of therapeutic targets for siRNA-based treatment of several ocular diseases tested in vivo.
IOP obtained using siRNA was similar to that found with drugs currently prescribed for glaucoma treatment such as dorzolamid, latanoprost or timolol (Mediero et al., 2009). However, the effect of the \( \beta_2 \)-adrenoceptor siRNA treatment was significantly longer in terms of time effect as compared with conventional pharmacological agents. While the commercial drugs reduced IOP for a few hours (around 8 h), the siRNA effect lasted for 2 days (Pintor, 2011). Therefore, the use of siRNA against \( \beta_2 \)-adrenoceptors produces a significant reduction in IOP that is long-lasting, whereas a continuous application of commercial drugs is required to induce a sustained effect on IOP. Moreover, this long-lasting effect was achieved by simple topical administration of the siRNA and the possible use of a non-viral vector carrier, which prevents siRNA degradation, may even prolong this hypotensive action of the siRNA.

This long-lasting reduction of IOP by siRNA may be one of the most attractive features of this new approach for glaucoma treatment as frequent application of some commercial anti-glaucoma drugs, currently used at high concentrations to achieve the desired therapeutic effects, can lead to adverse side effects due to systemic absorption (e.g. timolol can induce a deleterious effect on the heart). Additionally, a requirement for frequent instillation can lead to poor compliance of the patient, which represents another problem in glaucoma management.

Because of these promising results, phase I clinical trials have been carried out (Sylentis Company, Madrid, Spain). SLY040012 was topically administered to healthy volunteers and individuals with increased IOP. All of the subjects analysed showed excellent local and systemic tolerance, and SLY040012 was able to lower IOP in individuals with elevated IOP (Pañeda et al., 2013). Phase II clinical trials are currently ongoing with a dose–range finding study in which the efficacy of different doses of SLY040012 will be compared with placebo (Table 1).

This long-lasting effect in IOP reduction, compared to commercial drugs, was also apparent in studies where other siRNAs against different targets were used to reduce aqueous humour production. In this regard, the potential hypotensive effect of siRNAs targeting Na-K-ATPase subunits was tested in rabbits (Mediero et al., 2009). Na-K-ATPase was selected as a target as it establishes ion gradients in the ciliary epithelium that contribute to aqueous humour production (Riley and Kishida, 1986). The silencing of Na-K-ATPase induced a 15% IOP reduction in the treated rabbits and this hypotensive effect was maintained for around 100 h (Mediero et al., 2009).

Finally, it is worth mentioning another different target recently identified to reduce IOP, the purine receptor P2Y\(_2\). Elevated levels of agonists of this receptor (ATP and dinucleotides) have been found in the aqueous humour from glaucomatous patients (Zhang et al., 2007; Castany et al., 2011),
suggesting the involvement of these compounds in glaucoma pathology. In fact, it has been reported that activation of P2Y2 receptors present in rabbit ciliary processes by different nucleotides induces an increase in IOP (Markovskaya et al., 2008; Peral et al., 2009). On consideration of these findings, a siRNA targeting P2Y2 receptor has been developed (Martin-Gil et al., 2012). Topical application of the P2Y2 siRNA produced a robust decrease in IOP of 48 ± 5% in normotensive rabbits compared with control animals, with this maximal reduction in IOP remaining for 2 days. Once more, in terms of time of hypotensive effect, RNAi was more effective than commercial drugs.

Potential new targets aimed at improving aqueous humour outflow have also been proposed, although the biological data are preliminary and they have not been pharmacologically validated yet. These potential new targets are localized in the TM. To reach this location, siRNAs used in animal models have been solely administered by anterior chamber injection through the corneal limbus. However, it has been demonstrated that naked siRNAs can penetrate human TM when perfused at physiological pressure (Comes and Borras, 2007). This finding, together with the results obtained in the clinical trials (mentioned earlier), in which siRNAs were administered topically, suggests that this target has potential as an effective route of administration. Further research is needed to confirm this.

Many of these new targets are related to the ECM of TM. There is an important relationship between the structure of the ECM of TM and aqueous humour outflow. Excessive amounts of cross-linked ECM proteins in the TM have been associated with increased aqueous humour outflow resistance in glaucoma (Buller and Johnson, 1994). Consequently, various components of the ECM have become an important target for siRNA delivery to regulate aqueous humour outflow and lower IOP. In this sense, the TGF-β2 signalling mothers against decapentaplegic (Smad) pathway is known to regulate the ECM deposits in TM (Verrecchia and Mauviel, 2002). Down-regulation of Smad7 by RNAi interrupted the effects of TGF-β2 on the expression of several ECM components (fibronectin and laminin) in human TM cells in in vitro assays (Su et al., 2012). Likewise, silencing of other member of the Smad signalling pathway, Smad3, suppressed TGF-β2 induction of tissue transglutaminase, which is involved in cross-linking of ECM proteins (Tovar-Vidales et al., 2011).

Another critical mediator of the effects of TGF-β2 on the synthesis of ECM protein in TM cells appears to be the connective TGF (CTGF). Attenuation of CTGF expression by RNAi in cultured human TM cells prevented the TGF-β2-induced accumulation of fibronectin (Junglas et al., 2009). Interestingly, it has also recently been reported that depletion of CTGF by RNAi in cultured human TM cells causes a marked reduction in the actin cytoskeleton (Junglas et al., 2012). Disruption of TM actin stress fibres (Tian et al., 2000) evokes a reduction in outflow resistance; accordingly, siRNA against CTGF could provide a dual beneficial effect in the improvement of aqueous humour outflow in TM by both preventing ECM protein deposits and modifying the actin cytoskeleton.

However, because the contraction of actin stress fibres is predominantly regulated by the activity of RhoA/Rho kinase, the use of RhoA siRNA as a potential pharmaceutical intervention for reducing IOP has also been described (Liu et al., 2012). A liposome-RhoA siRNA complex, administered to mice by injection into the anterior chamber, caused a large decrease in the both the mRNA and protein expression of RhoA. Furthermore, siRNA silencing of RhoA in TM effectively decreased IOP in a mouse model with high IOP (Liu et al., 2012).

Cochlin is another potential target for siRNA glaucoma therapy localized in TM. Although its function has not been fully elucidated, it has been suggested that it has a role as a mechanosensor detecting fluid shear changes in ECM (Goel et al., 2012). TM cells in glaucomatous eyes are subjected to a significant level of fluid shear change due to IOP fluctuation. Cochlin multimerization is induced in response to fluid shear changes (Goel et al., 2012). This multimerized cochlins is resistant to proteolysis and accumulates in the TM ECM in glaucomatous eyes (Bhattacharya et al., 2005). These cochlins deposits observed in glaucomatous TM could obstruct aqueous outflow across a wide region and increase IOP. Silencing of cochlins by RNAi in the glaucoma mouse model DBA/2J reduced IOP and maintained low IOP levels for the next 2 months as compared with control injected eyes (Goel et al., 2012).

In a few glaucoma patients, deficiencies in the ability of the TM to manage aqueous humour outflow have been attributed to the deleterious effects of mutated myocilin (Fingert et al., 1999). Misfolded mutant myocilin accumulates in the endoplasmic reticulum, inducing endoplasmic reticulum stress and apoptosis of TM cells with subsequent obstruction of TM and increased resistance of aqueous humour outflow (Sohn et al., 2002). Yuan and co-workers (2007) designed different self-looped short hairpin RNAs as siRNA precursors to suppress mutant myocilin in TM5 cells. The expression of mutant, but also wild-type myocilin was reduced to around 60% of the control level in TM5 cells. Because these results were detected in vitro, myocilin siRNAs need to be evaluated in animal models before definitive conclusions about their potential clinical application.

Despite successful lowering of IOP, many glaucoma patients continue to have progressive retina and optic nerve damage, and others acquire damage at normal or low IOP, indicating that other factors contribute to the pathophysiology of glaucoma. This has led to the need to develop new therapeutic approaches focused on offering effective neuroprotection to preserve vision. Consequently, siRNA-based treatments to prevent apoptosis and provide ocular neuroprotection have also been proposed. Several siRNAs have been designed to target proteins related to the initiation or execution of the programmed cell death cascade in RGC such as c-Jun-amino-terminal kinase-interacting protein 1 (c-Jun), the pro-apoptotic Bcl-2 family member Bax and the mediator of caspase-induced cell death apoptotic protease-activating factor-1 (Apaf-1; Lingor et al., 2005). SiRNAs, injected into the optic nerve stump, were shown to inhibit axotomy-induced apoptosis in rats. Rat retinas that were injected with Apaf-1 siRNA and c-Jun siRNA showed significantly more surviving RGC than non-injected or eGFP siRNA-injected controls (approximately two- to threefold respectively). Bax siRNA-injected retinas tended to have increased RGC numbers, but the levels reached were not significant (Lingor et al., 2005).

The siRNA targeting caspase-2 has also been demonstrated to have a neuroprotective action. A single intravitreal
injection of this siRNA protected RGC during the first week after optic nerve crush (ONC), maintaining enhanced survival for 30 days after ONC (Ahmed et al., 2011). Likewise, caspase-2 siRNA significantly improved RGC survival in the more severe and prolonged optic nerve transection (axotomy) rat model (Ahmed et al., 2011).

Despite these promising results, as yet no clinical evidence exists about the neuroprotective action of these siRNAs preventing disease progression in patients with glaucoma.

**Fibrotic eye**

Filtration surgery to enhance the drainage of the eye is the most effective method for reducing IOP in patients with glaucoma that is refractory to topical ocular hypotensive treatments (The AGIS Investigators, 2000). However, the post-operative healing response can render the outcome of such surgery unsuccessful if scar formation increases outflow resistance of the artificially generated drainage pathway. The wound healing response at the operated site is characterized by several molecular events that include cell proliferation (particularly subconjunctival Tenon’s capsule fibroblasts proliferation; Jampel et al., 1988), enhanced expression of ECM proteins (Saika et al., 2001) and inflammation (Chang et al., 2001b). Different approaches to modulate these processes during the wound healing response after filtering surgery by RNAi have been proposed. Nakamura et al. (2004) using RNAi targeting TGF-β2 reported a significant reduction in the inflammatory response and matrix deposition in a mouse model of subconjunctival scarring. Recently, the siRNA silencing of secreted protein acidic and rich in cysteine (SPARC) has also shown to reduce the pro-fibrotic TGF-β2 in in vitro experiments with human Tenon’s fibroblasts (Seet et al., 2012). Likewise, SPARC down-regulation induced a cell migration delay, reduced collagen contractility as well as the expression of other pro-fibrotic and pro-inflammatory genes, which indicates that SPARC silencing has potential as an anti-fibrotic strategy. Furthermore, the effects of siRNA silencing SPARC were compared with those of mitomycin C, which is commonly used to attenuate the pathological progress of autosomal-dominant RP, rhodopsin mRNA silencing by siRNAs, using two different approaches, has been proposed. The first approach includes the use of allele-specific siRNAs, which block the expression of mutant transcripts while allowing normal expression of wild-type alleles (Hernan et al., 2011). However, the preferential silencing of a common dominant rhodopsin mutation was not sufficient to inhibit retinal degeneration in a transgenic rat model (Tessitore et al., 2006). Moreover, the considerable heterogeneity among rhodopsin gene mutations would require the development of individual therapeutics for each mutation, which would represent an expensive and time-consuming process. To circumvent this limitation an alternative strategy consisting of mutation-independent RNAi suppression and gene replacement has been proposed. In essence, the approach involves suppression of both mutant and wild-type alleles of the rhodopsin gene by siRNAs (Cashman et al., 2005; Kiang et al., 2005; Gorbatyuk et al., 2007) and concomitant provision of the rhodopsin gene, which has been sequence-modified to evade suppression. Using this approach, O’Reilly and colleagues (2007) demonstrated a substantial RNAi-based suppression of rhodopsin mRNA and the effective expression of RNAi-resistant replacement genes in the presence of siRNAs in mice subretinally injected with adeno-associated virus expressing both a siRNA
and a replacement rhodopsin. Likewise, intravitreal injection of this adeno-associated virus induced a short-term (10 day) beneficial effect in the outer nuclear layer of the mouse simulating human rhodopsin-linked RP with a mutation consisting of proline-23 substituted by histidine (P23H). More recently, a long-term restoration of retinal structure and function by mutant-independent rhodopsin siRNA combined with rhodopsin RNA replacement was observed in these P23H rhodopsin transgenic RP mice (Mao et al., 2012). At 9 months post-injection, the outer nuclear layer and rod outer segment thickness were significantly increased in the treated compared to control eyes. The improved survival of photoreceptors was concomitant with the preservation of an electroretinogram response.

Other genes associated with autosomal-dominant RP such as retinal degeneration slow-peripherin have similarly been a target for RNAi-based suppression coupled with gene replacement technology for the development of RP therapies (Palfi et al., 2006; Petrs-Silva et al., 2012). Alternatively, a combined therapy introducing wild-type photoreceptor PDE-6 expression and knocking-down guanylate cyclase or cyclic nucleotide-gated ion channels by RNAi has been proposed to prevent an excessive influx of calcium leading to photoreceptor cell death in RP (Tosi et al., 2011).

Despite all these promising results, the possibility that the combined use of RNAi and gene therapy could also have potential adverse effects must not be overlooked. For instance, more data from animal models are required to fully assess the potential risk of insertional mutagenesis from integrating vectors, even the mostly episomal adeno-associated virus vectors.

Age-related macular degeneration

AMD is the leading cause of irreversible blindness in the Western world (Chopdar et al., 2003), with an estimated prevalence of 30–50 million persons.

AMD is a progressive disease that affects the central portion of the retina (the macula). In the earliest stage, deposits called drusen form in the area between the retinal pigment epithelium and the underlying choroid. Advanced AMD, responsible for profound vision loss, has two forms: dry and wet. The dry form of advanced AMD results from atrophy of the retinal pigment epithelial layer below the retina. In wet AMD (neovascular AMD), the principal cause of severe vision loss is the invasion of aberrant blood vessels into the retina from the choroid, a pathological process known as choroidal neovascularization (CNV).

In the past few years, therapeutic intervention for AMD has shifted from a predominantly laser-based treatment approach to a more targeted pharmacotherapeutic strategy (Emerson and Lauer, 2008). As VEGF and its receptor VEGFR1 are critical molecules in the pathogenesis of CNV, several anti-VEGF drugs have been developed (Campa and Harding, 2011). Two agents have been approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD: pegaptanib (Macugen®, a pegylated aptamer that targets VEGF165 isoform) and ranibizumab (Lucentis®, a humanized monoclonal antibody fragment against VEGF). Also, bevacizumab (Avastin®), a full-length recombinant humanized anti-VEGF antibody, originally approved by the FDA for cancer therapy, is widely used to treat patients with AMD. These last two agents, ranibizumab and bevacizumab, appear to be more efficacious than pegaptanib (Emerson and Lauer, 2008).

Similarly, the siRNA strategy for AMD has been mainly based on the blocking the expression of VEGF and VEGFR1 mRNA. The potency of siRNA against VEGF is thought to be 100–1000 times greater than that of VEGF protein antagonists due to the mechanism of action of RNAi (Gu et al., 2010). Moreover, siRNA-induced suppression of VEGF production may allow the time intervals between the administrations by intravitreal injections to be increased, so decreasing the risk of toxicity or infection.

Reich et al. (2003) tested the ability of siRNA targeting VEGF to reduce growth and vascular permeability in a murine laser-induced model of CNV. The area of CNV was significantly less in eyes that had received a subretinal injection of VEGF siRNA as compared with those injected with GFP siRNA. Similarly, in another study, both intravitreal and periocular injections of siRNA directed against VEGFR1 (siRNA-027) significantly reduced VEGFR1 mRNA levels and suppressed the development of CNV in mice with oxygen-induced ischaemic retinopathy (Shen et al., 2006).

In view of these hopeful results in animals, two pioneering human trials with siRNAs were conducted in the eye. Naked siRNAs targeting VEGFA (bevasiranib) or one of its receptors VEGFR1 (siRNA-027/AGN 211745), administered intravitreally, were tested as drug candidates in clinical trials with CNV due to AMD (Table 1). The randomized, double-blind, phase II study with bevasiranib (Opko Health Inc., Miami, FL, USA) compared three doses (0.2, 1.5 or 3.0 mg) injected intravitreally 6 weeks apart in 129 patients with CNV secondary to AMD (Brucker, 2006). The safety data were encouraging; however, bevasiranib-treated patients lost visual acuity over 18 weeks and lesion size also increased, as measured by fluorescein angiography at 12 weeks. Compared with the improvement in vision seen with other therapies, including ranibizumab and bevacizumab, the vision loss in these patients does not bode well for the use of bevasiranib as a monotherapy. Because bevasiranib only inhibits new VEGF synthesis, but does not eliminate the VEGF already present in the eye at the time of administration, the effect of the compound on CNV can appear to be delayed. For this reason, a phase III trial evaluating the combination of bevasiranib and ranibizumab in 330 patients with neovascular AMD was performed (ClinicalTrials, 2008). More than 30% of the subjects who received ranibizumab followed by bevasiranib showed an improvement of at least three lines of visual acuity. The greatest difference compared with the group treated with ranibizumab only was at 6 weeks. These preliminary results suggested a possible benefit of using ranibizumab–bevasiranib combination therapy to treat AMD. However, Opko Health decided to terminate its phase III trial prematurely, after the Independent Data Monitoring Committee found that, although bevasiranib showed activity when used in conjunction with ranibizumab and safety was acceptable, the trial was unlikely to meet its primary end point. Similarly, a clinical trial of the siRNA AGN211745 targeting VEGFR1 (formerly siRNA-027; Allergan Inc., Irvine, CA, USA) was also halted, despite initial positive reports of efficacy from an
earlier study enrolling 26 patients with CNV resulting from AMD (Kaiser et al., 2010). No safety issues were associated with AGN211745 targeting VEGFR1, but it failed to meet a key efficacy in a phase II study.

Importantly, while these clinical studies were being conducted, a shocking discovery was reported by Kleinman et al. (2008). These authors demonstrated that the suppression of neovascularization is a generic property of siRNAs independent of sequence and target. siRNAs of 21 nt (but not shorter siRNAs), with different sequences and targets, showed an anti-angiogenic effect. This effect is mediated by the binding of any 21 nt siRNA to TLR3. This results in receptor dimerization and NF-κB activation of genes encoding IFN-γ and IL-12, which, it seems, are the effectors of the anti-angiogenesis. In this scheme of events, therefore, inhibition of angiogenesis does not seem to occur through the specific action of siRNAs in suppressing the messenger RNA of VEGF or its receptor.

Further studies also confirmed that 21 nt siRNAs, regardless of their targeting sequences, are able to inhibit experimental CNV in mice (Ashikari et al., 2010; Gu et al., 2010). Moreover, a recent study has determined that 21 nt siRNAs can induce caspase-3-mediated apoptotic death of retinal pigmented epithelial cells in mice by activating surface TLR3 and subsequent nuclear translocation of IFN regulatory factor-3 (Kleinman et al., 2012). Retinal pigment epithelium degeneration was not observed after treatment with siRNAs shorter than 21 nt. Accordingly, in order to enhance therapeutic specificity and avoid dsRNA-induced retinal pigment epithelium toxicity, the use of siRNAs (small interference RNA or RNAi) with lengths below 21 nt should be considered. In this context, PF-04523655 (also known as PF-655), an siRNA (19 nt in length) with 2′-O-methyl nucleosides in every pair of oligonucleotide sequences, is in development for the treatment of wet AMD. PF-655 inhibits the expression of the hypoxia-inducible RTP801 gene, which plays a critical role in the pathological process of acute or chronic stress-induced retinal disease and potentiates VEGF expression during hypoxic stress (Brafman et al., 2004). The methylation and short length of this siRNA are considered to prevent TLR3 activation and immune stimulation (Kariko et al., 2005), and, certainly experimental evidence confirmed that PF-655 produced gene silencing into the retinal cells while avoiding TLR3 activation (Feinstein et al., 2009). Moreover, methylation could prevent its degradation (Chiu and Rana, 2003).

In animal models of laser-induced CNV, intravitreal injection of PF-655 reduced CNV formation and vessel leakage (Nozaki et al., 2006). In addition, this siRNA targeting RTP801 gene is currently in clinical trials for the treatment of wet AMD. A phase I trial testing the efficacy and safety of stable, modified PF-655 administered alone by intravitreal injection (Nguyen et al., 2012b), and a phase II study (MONET) comparing PF-655 efficacy with that of ranibizumab as well as a ranibizumab/PF-655 combination therapy versus ranibizumab monotherapy (Nguyen et al., 2012c) have recently been performed (Table 1). The best-corrected visual acuity in AMD patients treated with PF-655 alone was less than that in the ranibizumab group. In contrast, the ranibizumab/PF-655 combination group achieved a numerically greater improvement in mean best-corrected visual acuity from baseline than the ranibizumab group at week 16, although the difference was not statistically significant. Regarding the results of anatomic measurements, the combination (ranibizumab/PF-655) and ranibizumab monotherapy groups had similar mean reductions in central subfield retinal thickness and total CNV area, which were greater than those of the PF-655 monotherapy group.

Thus, despite its favourable structural and chemical properties suggesting that PF-655 should be more effective than other siRNAs for the treatment of neovascular AMD, the clinical trial results indicate that PF-655 monotherapy did not improve AMD as compared with standard of care monotherapy (ranibizumab). However, the combination therapy (ranibizumab/PF-655) showed promising results with an improvement in best-corrected visual acuity in AMD patients as compared with patients treated with only ranibizumab.

However, although anti-VEGF agents such as ranibizumab or bevacizumab are clearly important therapeutic breakthroughs in the treatment of AMD, there are increasing concerns regarding their long-term safety profile because systemic and local side effects can occur. Firstly, although the drugs are administered by intravitreous injection, systemic side effects caused by VEGF blockade can still occur. Thus, systemic exposure to anti-VEGF agents is associated with heightened risks of systemic thromboembolic complications, such as systemic hypertension, stroke, myocardial infarction as well as non-ocular (e.g. gastric and renal) haemorrhage (Costagliola et al., 2012). Secondly, it is also important to remember that VEGF is an important factor in retinal physiology. In fact, VEGF protects RGCs from insults such as H2O2-mediated oxidative stress (Brar et al., 2010). Furthermore, it has recently been reported that VEGF has an essential trophic role in maintaining a healthy choroid vasculature and cone photoreceptors (Kurihara et al., 2012). VEGF deletion in adult mouse retinal pigmented epithelial cells causes rapid retinal dysfunction, especially in cone receptors, whereas deletion of the upstream regulatory transcriptional factors, hypoxia-inducible transcription factors (HIFs), does not produce vision loss. Yet, elimination of these HIFs prevented pathological angiogenesis in a laser photocoagulation model of CNV (Kurihara et al., 2012).

Targeting factors upstream of VEGF may be therapeutically advantageous compared with direct VEGF antagonists, which may have more off-target inhibitory trophic effects. From this perspective, PF-655 siRNA treatment could have the benefit of avoiding the detrimental long-term side effects associated with current anti-VEGF drugs. Alternatively, bearing in mind the clinical trial results with PF-655 siRNA, a sequential combination therapy, which would include an initial treatment with an anti-VEGF drug like ranibizumab followed by maintenance with PF-655 siRNA as a long-term therapy, could be another strategy.

Diabetic retinopathy

DR is a common complication of diabetes, and because the worldwide prevalence of diabetes mellitus continues to increase (it is expected to affect an estimated 500 million by 2030), DR remains a leading cause of vision loss in many
developed countries (Congdon et al., 2003; Cheung et al., 2010).

DR is a microvascular disease characterized by vessel basement membrane thickening, blood–retinal barrier breakdown, capillary cell death, acellular capillary, neovascularization and retinal detachment (Cheung et al., 2010). In addition to vascular abnormalities, glial dysfunction and death of retinal neurons also occur in DR.

Pathophysiological mechanisms responsible for the development of this slow-progressing disease have not been fully elucidated yet. Chronic exposure to hyperglycaemia is believed to initiate several biochemical pathways (accumulation of sorbitol and advanced glycation end products, increased oxidative stress, up-regulation of the renin–angiotensin system and VEGF), inducing pathophysiological changes that finally produce microvascular damage and retinal dysfunction (Robinson et al., 2012). Among the pathological changes that occur early and are linked causally to the development of retinopathy in diabetes are inflammation, altered ECM gene expression, and premature death of retinal capillary cells, photoreceptors and ganglion cells (Antonetti et al., 2006; 2012; Gastinger et al., 2006; Kern, 2007).

Laser retinal photocoagulation is the mainstay of ophthalmic therapy for vision-threatening DR.

However, laser treatment reduces the risk of moderate visual loss by approximately 50%, with no significant recovery of vision (Iacono et al., 2010). Moreover, the destructive nature of laser therapy is associated with significant ocular side effects. Thus, new approaches for the treatment of DR have emerged, such as intraocular administration of the anti-VEGF agent ranibizumab (Cheung et al., 2010; Iacono et al., 2010).

Similarly, siRNAs targeting VEGF (bevasiranib) or its receptor VEGFR1 (siRNA-027) designed to inhibit the choroidal neovascularization that occurs in AMD have also been tested, and the results were obtained in mouse models of retinal neovascularization, the process associated with DR, have so far been promising (Reich et al., 2006; Shen et al., 2003). Despite these results, clinical trials using these siRNAs have not been conducted in patients with DR, presumably due to previously failed clinical trials with AMD patients. In contrast, recently, a phase II clinical trial (DEGAS) of the siRNA PF-655, which blocks the RTP801 hypoxia/stress pathway, has been completed in DR patients (Nguyen et al., 2012a; Table 1). This clinical trial was designed to evaluate the effects of three dose levels (0.4, 1.0 and 3.0 mg) of PF-655 compared with laser photocoagulation therapy.

All three dose levels of PF-655 improved visual acuity from baseline by month 12 in the patients. The improvement in best-corrected visual acuity from baseline occurred within the first month after the intravitreal injection of PF-655, and by 6 months, a dose–dependent effect was evident that was maintained until month 12. Both the 1 and 3 mg doses produced greater mean gains in visual acuity than laser therapy. Because there were no dose-limiting toxicities, studies of higher doses (>3 mg) are planned to determine the optimal efficacious dose of PF-655. Moreover, in the future trial the efficacy of higher doses of PF-655 will be compared with those of ranibizumab. Considering the adverse events associated with long-term treatment with anti-VEGF drugs like ranibizumab, as already discussed, intravitreous administration of PF-655 may be a more desirable approach for DR treatment.

Likewise, siRNA targeting of other factors upstream of VEGF, such as the hypoxia-inducible factor-1α (HIF-1α), could be a safer option than using the current anti-VEGF drugs. It has been reported that the silencing of HIF-1α is effective at inhibiting retinal neovascularization in experimental mouse models (Jiang et al., 2009).

However, the elucidation of VEGF-independent pathways involved in the pathological progress of DR has provided new potential targets for the design of siRNA-based therapies that could offer future treatment strategies. Thus, as indicated earlier, hyperglycaemia modifies the expression of the ECM gene inducing an excess synthesis of retinal capillary basement membrane components such as fibronectin, collagen type IV and laminin (Evans et al., 2000; Oshitari et al., 2006). The consequent retinal capillary basement membrane thickening is a long-lasting lesion of DR and promotes other characteristic lesions, including acellular capillaries and pericyte loss, vascular leakage and a disturbance in the overall vascular homeostasis (Roy et al., 2003; Oshitari et al., 2006). Bearing this in mind, a siRNA strategy targeting ECM components has been shown to prevent basement membrane thickening (Roy et al., 2011). In streptozotocin-induced diabetic rats, intravitreal injection of a siRNA targeting fibronectin over a period of 4.5 months (at 6 week intervals) significantly reduced basement membrane thickening. Fibronectin siRNA treatment also prevented the loss of pericytes and formation of acellular capillaries, suggesting that fibronectin siRNA could be an effective preventative strategy in patients with DR. Other possible approaches also based on the prevention of ECM protein increase are the use of a siRNA against CTGF. This is a profibrotic factor that induces ECM production, angiogenesis and apoptosis (Brigstock, 2003; van Setten et al., 2005; Liu et al., 2008), and its levels are significantly increased in the retinas of diabetic rats (Winkler et al., 2012). Treatment of diabetic rats with CTGF siRNA decreased laminin β1 and collagen IV mRNA levels whereas fibronectin mRNA levels remain unchanged (Winkler et al., 2012).

Remarkably, intravitreal injection of CTGF siRNA in streptozotocin-induced diabetic rats not only reduced laminin β1 and collagen IV mRNA levels, but also inhibited VEGF and TGF-β2 expression (Yang et al., 2010a), and ameliorated retinal cell apoptosis (Yang et al., 2010b). Collectively, these findings indicate the key role that CTGF plays in DR development and support the potential ability of a CTGF siRNA-based treatment as a therapy for DR.

Thioredoxin-interacting protein (TXNIP) has recently been described as another potential gene target for preventing neovascular injury/cell death and the pathogenesis of DR (Devi et al., 2012). TXNIP is significantly increased in the diabetic rat retina (Perrone et al., 2009) and causes pro-inflammatory gene expression of VEGFA, COX-2, Intercellular Adhesion Molecule 1 and sclerotic fibronectin (Perrone et al., 2009; 2010; Sbai et al., 2010). Knock-down of TXNIP by siRNA was found to prevent the early abnormalities associated with DR in streptozocin-induced diabetic rats, such as retinal inflammation, fibrosis, gliosis and neuronal injury/apoptosis (Perrone et al., 2010; Sbai et al., 2010; Devi et al., 2012).
Corneal neovascularization

Corneal neovascularization is an important cause of blindness that affects up to 4.14% of patients presenting for eye care (Bachmann et al., 2010). Ischaemia, trauma, inflammation and rejection of corneal transplants can induce corneal neovascularization (Tshionyi et al., 2012). Infectious keratitis, caused by a virus, bacteria or fungi, can also lead to corneal neovascularization (Chang et al., 2001a). Interestingly, the use of a TLR2 siRNA to reduce the inflammation induced by fungal infection, was recently found to also prevent the subsequent severe damage (i.e. corneal neovascularization) to the cornea (Guo et al., 2012).

Other causes of corneal neovascularization include the overuse of contact lenses, chemical burns, limbal stem cell deficiency or degenerative diseases (Chang et al., 2012).

Current treatments for corneal neovascularization include topical corticosteroid and non-steroid anti-inflammatory medications, photodynamic therapy, laser photocoagulation, fine needle diathermy and conjunctival, limbal and amniotic membrane transplantation (Gupta and Illingworth, 2011). Unfortunately, these all have limited clinical efficacy and also cause undesirable side effects, such as the elevated IOP and posterior subcapsular cataracts subsequent to corticosteroid use.

There is an overlap in the molecular signals involved in the development of corneal neovascularization with those involved in retinal and CNV, although there are also differences as there are among most vascular beds either within or outside the eye (Oshima et al., 2005). One similarity for all these neovascularization processes is the involvement of VEGF, and therapeutic approaches based on anti-VEGF agents such as bevacizumab are being investigated (Chang et al., 2012). Likewise, siRNAs targeting VEGF or its receptors have been tested in several animal models of corneal neovascularization. Kim et al. (2004) reported that i.v. administration (administered via the polymer vehicle TargeTran) or subconjunctival administration of siRNAs targeting VEGFA, VEGFR1 and VEGFR2 into mice led to a significant reduction in the corneal neovascularization induced by herpetic simplex virus infection or CpG oligodeoxynucleotides. The combination of all three siRNAs provided the maximal effectiveness (~60% reduction in neovascularization). Consistent with these results, subconjunctival injection of siRNA targeting VEGFA in mice eyes in which corneal neovascularization was induced by an alkali burn, reduced VEGF expression, the neovascularized area, as well as the number of new vessels (Zuo et al., 2010).

In another example, intrastromal delivery of a plasmid expressing siRNA against VEGF suppressed injury-induced VEGF production, leukocyte infiltration and angiogenesis, and was able to reverse the corneal neovascularization (Singh et al., 2007). In particular, the suppression of neovascularization exceeded 73% as compared with the 30–50% reduction observed with the anti-VEGF antibodies bevacizumab and ranibizumab (Dursun et al., 2012).

Further, an intrastromal injection of poly(lactic co-glycolic acid) nanoparticles loaded with the plasmid expressing siRNA against VEGF has been shown to reverse the corneal neovascularization in a more sustained and robust manner than the naked plasmid alone, suggesting its usefulness as a therapeutic tool for sustainable and effective treatment of corneal neovascularization (Qazi et al., 2012).

Research on the development of new anti-VEGF siRNA therapies for corneal neovascularization has also been focused on the inhibition of upstream regulators of VEGF expression and action. Hence, the silencing of HIF-1α significantly reduced VEGF expression and corneal neovascularization (about 69–72% at day 10) in a mouse model of closed eye contact lens wear (Chen et al., 2012). Another regulator of VEGF expression in the cornea is the enzyme CYP4B1, a cytochrome P450 enzyme that metabolizes arachidonic acid to the potent inflammatory and angiogenic 12-hydroxyeicosatetraenoic acid (Mezentsev et al., 2005). siRNA targeting CYP4B1 greatly diminished VEGF mRNA levels (75% reduction) and attenuated the corneal neovascular response in a rabbit model of inflammatory neovascularization (Seta et al., 2007). The cannabinoid CB1 receptor has also been considered as a novel target. Down-regulation of CB1 receptors by RNAi inhibited both basic fibroblast growth factor- and VEGF-induced angiogenesis in in vitro experiments with human umbilical vein endothelial cells and in rabbit cornea assays in vivo (Pisanti et al., 2011).

These targets upstream of VEGF could be interesting alternative when taking into account the detrimental side effects coupled to long-term direct anti-VEGF therapy.

Concluding remarks and futures perspectives

siRNA technology holds great promise for the treatment of several ocular disorders that affect both the anterior and the posterior segment of the eye. However, implementation of safe siRNA-based ocular therapies might be more challenging than originally thought as there are still a number of concerns about the safety and true specificity of the current generation of siRNAs. On a positive note, the range of non-specific effects observed in siRNA studies is becoming better defined, as well as the approaches to reduce them. In terms of safety, further long-term studies are required, as long-term data in animals are still limited and it is entirely feasible that toxic effects will not show up for months, or perhaps even years.

Moreover, although the eye is a good target for this type of molecule mainly because it is a confined compartment and their delivery is close to the target site, the use of controlled and/or targeted delivery systems is recommended to improve the efficiency of siRNA therapy. These systems can provide protection against degradation, increase the intracellular penetration and permit long-term delivery, avoiding repeated administrations. Sustained siRNA levels could be particularly valuable for minimizing the number of intraocular injections needed to treat posterior segment diseases, as repetitive injections increase the risk of deleterious side effects.

Despite the therapeutic potential expected for RNAi, the reality is that the results obtained with siRNAs in the first clinical trials, which focused on AMD treatment, were not better than those obtained with other pharmacological treatments, at least, when siRNAs were applied alone. However, combining existing drugs with RNAi treatment improved the
results, indicating that this combination approach could provide an interesting therapeutic strategy. Although siRNAs did not completely succeed in clinical trials for AMD treatment, their potential merits continue to inspire research. In this way, several siRNAs have been tested for glaucoma treatment and clinical trials are ongoing. Their use offers a significant advantage as compared with conventional drugs as they were found to produce a more sustained reduction in IOP, circumventing the drawbacks associated with a requirement of frequent injections. Moreover, the RNAi strategy is particularly attractive for the treatment of ocular pathologies that do not have a specific cure such as RP.

Future advances in improving the safety, efficiency and duration of action of siRNAs will make it possible to maximize the clinical significance of RNAi technology for the treatment of ocular diseases.

**Acknowledgements**

This work was supported by Universidad Complutense de Madrid (Project GR35/10-A-920777), the Ministry of Economy (SAF 2010/16024) and the Institute Carlos III (Redes temáticas de investigación cooperativa en salud RD12/0034/0003).

**Conflict of interest**

The authors confirm that there are no conflicts of interest.

**References**


siRNA for ocular therapy

BJP


745


Winkler JL, Kedees MH, Guz Y, Teitelman G (2012). Inhibition of connective tissue growth factor by small interfering ribonucleic acid
prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy. Mol Vis 18: 874–886.


